Optimizing Advances in Nanoparticle Delivery for Cancer Immunotherapy
- 1 April 2019
- journal article
- review article
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 144, 3-15
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health/National Cancer Institute (U54CA198999, R01 EB25651)
- Department of Defense (W81XWH-16-1-0530)
- The University of North Carolina’s Research Opportunities Initiative grant
This publication has 161 references indexed in Scilit:
- Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemiaBlood, 2013
- Reprogramming Tumor-Associated Dendritic Cells In Vivo Using miRNA Mimetics Triggers Protective Immunity against Ovarian CancerCancer Research, 2012
- Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on sizeNature Nanotechnology, 2011
- Resistance to EGFR-Targeted Therapy: A Family AffairCancer Cell, 2011
- STING is a direct innate immune sensor of cyclic di-GMPNature, 2011
- The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effectAdvanced Drug Delivery Reviews, 2011
- CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid PhagocytosisCell, 2009
- Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapyJournal of Experimental Medicine, 2006
- Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acidsJournal of Controlled Release, 2005
- Exploring polyethylenimine‐mediated DNA transfection and the proton sponge hypothesisThe Journal of Gene Medicine, 2004